ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents

Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Info

Publication number
ATE435302T1
ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
Authority
AT
Austria
Prior art keywords
rivastigmine
determination
treatment success
apoe genotype
predicting treatment
Prior art date
Application number
AT03747881T
Other languages
English (en)
Inventor
Roger Lane
Mihael Polymeropoulos
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE435302T1 publication Critical patent/ATE435302T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT03747881T 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken ATE435302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
ATE435302T1 true ATE435302T1 (de) 2009-07-15

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747881T ATE435302T1 (de) 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Country Status (14)

Country Link
US (3) US20060160079A1 (de)
EP (1) EP1529116B1 (de)
JP (1) JP2005534710A (de)
CN (1) CN1681941A (de)
AT (1) ATE435302T1 (de)
AU (1) AU2003266967B2 (de)
BR (1) BR0313588A (de)
CA (1) CA2494585A1 (de)
DE (1) DE60328198D1 (de)
DK (1) DK1529116T3 (de)
ES (1) ES2327914T3 (de)
IL (1) IL166466A0 (de)
PT (1) PT1529116E (de)
WO (1) WO2004015140A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
CA2571856A1 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
WO2006083854A2 (en) * 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
CN110891417B (zh) 2017-03-21 2023-05-23 杰克逊实验室 表达人APOE4和小鼠Trem2 p.R47H的遗传修饰小鼠及其使用方法
BR112019001145A2 (pt) * 2017-05-24 2019-04-30 H. Lundbeck A/S combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
US20210195879A1 (en) * 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
JP7654202B2 (ja) * 2019-02-28 2025-04-01 ザ ロックフェラー ユニバーシティー がんの予後及び治療におけるａｐｏｅ遺伝子型決定
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
CN117886933A (zh) * 2023-12-28 2024-04-16 上海良润生物医药科技有限公司 一种载脂蛋白e检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインｅ４特異モノクローナル抗体
EP1121104B1 (de) * 1998-10-01 2005-01-12 Novartis AG Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物

Also Published As

Publication number Publication date
EP1529116A1 (de) 2005-05-11
WO2004015140A1 (en) 2004-02-19
US20100240744A1 (en) 2010-09-23
AU2003266967B2 (en) 2006-11-16
PT1529116E (pt) 2009-09-10
ES2327914T3 (es) 2009-11-05
JP2005534710A (ja) 2005-11-17
US20080214662A1 (en) 2008-09-04
AU2003266967A1 (en) 2004-02-25
BR0313588A (pt) 2005-07-12
IL166466A0 (en) 2006-01-15
DE60328198D1 (de) 2009-08-13
CN1681941A (zh) 2005-10-12
EP1529116B1 (de) 2009-07-01
DK1529116T3 (da) 2009-11-09
US20060160079A1 (en) 2006-07-20
CA2494585A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
ATE435302T1 (de) Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
EP1788938A4 (de) System, software und verfahren zur detektion von schlafgestörter atmung mithilfe eines elektrokardiogramms
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
WO2004101806A3 (en) Allele-specific expression patterns
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
ATE469245T1 (de) Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
DE602006007734D1 (de) Verfahren und system zur echtzeitanalyse von biosensordaten
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE331784T1 (de) Verfahren zur diagnose von fettsucht

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1529116

Country of ref document: EP

REN Ceased due to non-payment of the annual fee